Search - tctmd.com

Displaying 1 - 20 of 61

Sort: Relevancy | Date

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

L.A. McKeown

May 10, 2024

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Conference News LINC 2023

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

L.A. McKeown

June 08, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Daily News

AHA Outlines Diagnosis, Treatment Options for Underrecognized Critical Limb Ischemia

Caitlin E. Cox

August 12, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Daily News

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Caitlin E. Cox

June 18, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Features

Peripheral Vision: As Office-Based Practices Proliferate, Who Is Watching Out for Patients?

Caitlin E. Cox

May 01, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

Advertisement

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

AHA Outlines Diagnosis, Treatment Options for Underrecognized Critical Limb Ischemia

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Peripheral Vision: As Office-Based Practices Proliferate, Who Is Watching Out for Patients?

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content